Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases 

Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment 

Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker 

Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody  

Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel 

Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor  

Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib 

Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments 

Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target 

Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer